Video

Rescheduling Breast Reconstruction Post-Pandemic Will Present 'Interesting Logistical Puzzle' For Some

Author(s):

As patients begin to look at what’s to come when lockdown measures in place are relaxed a new logistical puzzle will pop for some.

Patients seeking reconstructive breast surgery after surgical centers are allowed to reopen after COVID-19 should trust their regional health systems to triage cases in a responsible fashion and expect them to be handled on a priority basis, according to one expert.

As the novel coronavirus has spread across the world, all elective surgeries, including breast reconstruction, have been delayed. Many women with breast cancer may wonder what might happen once plastic surgeons are given the greenlight to reopen and schedule reconstructive surgeries again.

In an interview with CURE®, Dr. Jonathan Bank, a board-certified plastic surgeon at New York Breast Reconstruction and Aesthetic (NYBRA) Plastic Surgery, discussed the planning that will go on to ensure there is very limited disruption to rescheduling appointments, as well as certain instances where challenges might ensue.

“… Trust your regional health system to triage the cases in a responsible fashion,” Bank, who specializes in breast reconstruction after cancer, said. “There's going to be a combination of administrators, but also professional medical staff that, in consultation with doctors that are managing the specific cases, will come to an understanding. I'm sure there is going to be extensive planning and just dealing with things on a priority basis.”

Bank explained that most hospitals and surgical centers allot surgeons a certain amount of time either per week or per month to perform their scheduled procedures. In some instances, such as with NYBRA Plastic Surgery, surgeons will operate out of several sites to coordinate surgeries and allow flexibility to see more patients. However, Bank noted that not everyone operates out of several sites which could be tricky when trying to reschedule with patients.

“It’s going to be an interesting logistical puzzle to manage, but in this day and age we have to do what is good for all of us and see what happens when we do and when we don't, so I think this is just an extension to what the world is experiencing,” he said.

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.